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ABSTRACT 
Rutin (RT), an antioxidant drug, has been utilized to treat cerebral ischemia hence a sensitive quantification 
method for estimation of RT in brain homogenate is necessary to develop. This study aims to prepare RT loaded 
Chitosan Nanoparticles (RT-CS-NPs) develop and validate ultra-high performance liquid chromatography-
electrospray ionization-synapt mass spectrometric method Synapt Mass Spectrometry (Synapt MS) 
(UHPLC/ESI-QTOF-MS/MS) for quantification of RT in brain homogenate from Wistar rat. The process of 
chromatographic separation was carried out on Waters ACQUITY UPLC™ with the components of separation 
in detail as; column: BEH C-18 with dimension as 2.1 mm×100 mm and particle size 1.7 µm, mobile phase: ace-
tonitrile (85 % v/v/v): 2 mM ammonium formate (15 % v/v/v): formic acid (0.1 % v/v/v) and flow rate: 0.25 
mL/min. Liquid-liquid extraction method (LLE), in mixture, i.e. ethyl acetate:acetonitrile, was considered to 
optimize the recovery of analyte from the brain homogenate of Wistar rat. Over a total run time of 5 minutes, the 
elution time for RT and internal standard (IS), i.e. Tolbutamide, observed was 2.67 and 2.82 min respectively 
whereas the transition observed for RT and IS was at m/z 611.1023/303.1071 and 271.1263/155.1073, respec-
tively. Results, regarding various processes and parameters studied for RT as summarized, established a linear 
dynamic range over a concentration range of 1.00 ng/mL - 1000.0 ng/mL with r2; 0.9991±0.0010. Accuracy for 
intra and inter-assay in terms of % CV revealed a range of 0.45- 2.11 whereas lower limit of detection (LOD) 
and quantitation (LOQ) observed was 0.09 ng/mL and 0.142 ng/mL, respectively. The analyte stability as well as 
method specificity and accuracy, i.e. recovery > 86 %, supports the idea for application of current developed 
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method in order to quantify and evaluate the RT-loaded-CS-NPs for RT determination in brain homogenate after 
intranasal drug delivery. 
 
Keywords: Rutin, UHPLC-MS/MS-ESI-Q-TOF, method development and validation, chitosan nanoparticles, 
brain pharmacokinetic 
 
Abbreviations: UHPLC-MS/MS: Ultra high performance liquid chromatography mass spectroscopy and mass 
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INTRODUCTION 
Rutin, isolated from plants, i.e. Ruta 
graveolens and Carpobrotus edulis exhibits 
potent antioxidant activity. Recently, the re-
search studies on rutin revealed the effec-
tiveness of this drug in treating cerebral is-
chemia (Annapurna et al., 2013; Zhang et al., 
2013; Jang et al., 2014; Rodrigues et al., 
2013; Khan et al., 2009; Raza et al., 2011), 
however a major problem of low water solu-
bility hence low bioavailability still exist 
with rutin (Park et al., 2013; Veselova et al., 
2012; Sasikala et al., 2013). In addition, lit-
erature studies report rutin, a drug with lipo-
philic property (Baldisserotto et al., 2015; 
Viskupicová et al., 2015) and thus it is a 
well-known fact that oral delivery of lipo-
philic drugs including rutin encounters dif-
ferent problems such as i) permeability com-
plications leading to poor bioavailability ii) 
more prone to chemical and enzymatic deg-
radation in the gastrointestinal tract, and iii) 
extensive hepatic first-pass metabolism. The 
complications aforementioned necessitate 
effective solution in the form of intranasal 
drug administration for targeted therapy in 
brain with numerous advantages, i.e. ease of 
transportation for drug in significant amount 
into cerebrospinal fluid (CSF) and olfactory 
bulb, a safe, novel, painless, non-invasive 
and effective route of drug administration 
requiring less technical skills and effective 
for localized therapeutic effects (Ahmad et 
al., 2013, 2015; Wang et al., 2008). Till date 
different strategies in term of route of admin-
istration and formulations have been applied 
in order to enhance RT bioavailability and 
we hereby added up a strategy via formulat-
ing chitosan nanoparticles loaded with RT 
and administered intranasal.  
Likewise, literature survey (i.e. Zhang et 
al., 2010; Chen et al., 2015; Soares et al., 
2015; Cen et al., 2015) reports different 
methods for RT plasma analysis, however, 
most of these reported studies showed simul-
taneous development of RT plasma analysis 
in many drugs at the same time, i.e. no re-
ports of plasma analysis are available for RT 
individually. Besides, other important reason 
for current study are lack of research availa-
ble for brain tissue analysis of RT, unavaila-
bility of a sensitive bioanalytical method for 
estimation of plasma RT analysis alone as 
well as in brain tissue and above all lack of 
research studies for estimation of RT at 
picogram level in any of the plasma or brain 
tissue.  
Upto the best of our knowledge, current 
study is a first time study of its kind in order 
to develop and validate a bioanalytical meth-
od for RT encapsulated in CS nanoparticles 
via UHPLC/ESI-Q-TOF-MS/MS. The de-
veloped method showed wide application 
and more efficiency in terms of high sensi-
tivity and low retention time, for successful 
bioanalytical investigation in brain as well as 
brain pharmacokinetics. In addition, current 
method offers an extra advantage of rutin 
quantification in brain tissue. 
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MATERIALS AND METHODS 
Chitosan, i.e. medium molecular weight 
with degree of acetylation of 85 %, Glacial 
acetic acid from IOL Chemical Ltd (Mum-
bai, India), Sodium tripolyphosphate (TPP), 
Acetonitrile (LC-MS grade), Formic acid 
(LC-MS grade) and Methanol (LC-MS 
grade) were purchased from Sigma-Aldrich 
(St Louis, MO). Sodium hydroxide (NaOH), 
1-octanol, potassium dihydrogen phosphate, 
Ammonium formate (MS grade) and ammo-
nium acetate (MS grade) as well as Formic 
acid (purity > 98 %) were purchased from 
Fluka analytical (Sigma-Aldrich, the Nether-
land) and Fluka analytical (Germany) respec-
tively. The Milli-Q water purification sys-
tem, i.e. (Millipore, Bedfrod, MA, USA) was 
used for purification of Deionized water. A 
Sigma-Aldrich cellophane tube with dimen-
sions, i.e. Mol. wt. cut-off (12,000 Da), flat 
(25 mm), diameter (16 mm) and capacity (60 
mL/ft) was used in the study. 
 
Nanoformulation development of Chitosan 
nanoparticles (Ionic Gelation Method) 
Chitosan nanoparticles (CS-NPs) were 
prepared via ionic gelation techniques as re-
ported (Calvo et al., 1997; Aktas et al., 
2005). Placebo NPs were prepared initially 
which was attained as dropwise addition of 
aqueous solution of TTP (0.15 %) with a so-
lution of CS (0.15 %) while continuously 
stirring at room temperature. The mechanism 
behind formulation of placebo CS-NPs was 
ionic interaction between positively charged 
amino group form CS and negative groups of 
TTP, the final ratio for which was estab-
lished on the basis of preliminary studies. 
The same procedure was utilized for the 
preparation of RT-loaded CS-NPs, keeping 
the ratio for CS/TTP unchanged while the 
ratio for RT was varied in order to observe 
the effect of initial RT concentration upon 
the characteristics as well as the in-vitro re-
lease profile of NPs. Followed by centrifuga-
tion for 30 minutes at 4000 rpm and 4 °C and 
collection of CS-NPs after supernatant is 
discarded. 
Characterization of nanoparticles 
Particle size and zeta-potential  
measurements 
For the determination of particle size a 
Nano-series Zetasizer (Nano-ZS, HAS 3000, 
Malvern Instruments Ltd, Worcestershire, 
UK), based on the principle of photon corre-
lation spectroscopy, was used. In detail for 
the determination of zeta potential all the 
samples (NPs) were diluted properly with 
Milli-Q water (the dispersant dielectric con-
stant value for water set as 78.5) and the 
electrophoretic mobility was obtained at 
25 °C which was calculated finally with the 
help of DTS (version 4.1) software from 
(Malvern, Worcestershire, UK).  
Transmission electron microscopy (TEM)  
The surface morphology for prepared 
CS-NPs was determined with the help of 
TEM (Morgagni 268D; FEI Company, 
Hillsboro, OR). In detail one drop of nano-
suspension was put on a paraffin sheet suc-
cessively followed by covering with a copper 
grid, keeping for a time period of one (01) 
minute in order for the NPs to stick and at 
the end keeping the grid for a time of > 5 
seconds on one drop of phosphotungstate. 
The samples, after clearing the remaining 
solution with the help of filter paper, were 
air dried and observed again with TEM. 
Scanning electron microscopy (SEM)  
The surface texture for the optimized 
RT-CS-NPs was confirmed with the help of 
SEM (Zeiss EVO40; Carl Zeiss, Cambridge, 
UK). In detail the sample was spread on a 
double-sided conductive tape successively 
followed with stucking, under high vacuum 
with gold, in SCD020 Blazers sputter coater 
unit (BAL-TEC GmbH, Witten, Germany) 
where the environment was already main-
tained with argon gas (50 mA) for 100 sec-
onds. 
UHPLC conditions 
Waters ACQUITY UPLCTM system from 
Waters Corp., MA, USA, hyphenated with a 
binary system of solvent delivery and tunea-
ble MS detector (Synapt; Waters, Manches-
EXCLI Journal 2016;15:518-531 – ISSN 1611-2156 
Received: April 29, 2016, accepted: July 14, 2016, published: August 17, 2016 
 
 
 
521 
ter, UK), was used to perform the process of 
UHPLC whereas Waters ACQUITY UP-
LCTM BEH C-18 column with dimension, 
i.e. 2.1 mm × 100 mm, 1.7 µm was utilized 
for chromatographic separation. The UHPLC 
mobile phase conditions were as follows: 
degassed LC-MS grade solvent, i.e. Acetoni-
trile (85 %): 10 mM Ammonium Formate 
(15 %): Formic Acid (0.1 %), v/v/v, with 
isocratic elution, flow rate of 0.25 mL/min 
sample injection volume of 10 µl/run and a 
total chromatographic run time of 5.0 min. 
 
ESI-Q-TOF-MS conditions  
Waters Q-TOF Premier mass spectrome-
ter system (Micromass MS Technologies, 
Manchester, UK) was used to perform MS. 
The Q-TOF Premier TM operating condi-
tions were as follows: V mode operation 
with resolution over 32000 mass and scan 
time of 1.0 min whereas inter-scan delay of 
0.02 sec along with a collision gas, i.e. argon 
at a pressure 5.3×10-5 Torr. Synapt Mass 
Spectrometry (Synapt MS) used for quantifi-
cation (set for trap collision energy (Trap 
CE) at 26.8 and 24.64 eV) showed transi-
tions, i.e. RT at m/z 611.1023 and Tolbutam-
ide (IS) at m/z 271.1263, as shown in Fig-
ures 1 and 2. Mass Lynx software V 4.1 was 
used to calculate the accurate mass and com-
position for the precursor and fragment ions. 
 
 
Figure 1: Mass spectrum of (A) Rutin pa-
rent/protonated molecule at m/z 611.1023) and 
(B) Rutin product ion (major fragmented product 
ion at m/z 303.1071) showing fragmentation 
transitions 
 
Figure 2: Mass spectrum of (A) Tolbutamide (IS) 
protonated molecule at m/z 271.1263 and (B) IS 
product ion (major fragmented product ions at 
m/z 155.1073) showing fragmentation transitions 
 
Quality Control (QC) sample and standard 
sample preparation 
The requisite amount of RT was dis-
solved in methanol and sonicated for 20 
minutes at 44 kHz/250W in order to prepare 
a standard stock solution of 10 mg/mL for 
RT. A set of eight non-zero concentrations 
(A-H) for calibration curve (CC) standards 
were prepared as spiking aqueous analyte 
(2 %) in blank rat brain homogenate, i.e. 
20 ml (aqueous aliquots) + 980 ml (blank rat 
brain homogenate) which yielded a concen-
tration range for RT, i.e. 1–1000 ng/mL. For 
each analyte the final concentration ended up 
with 1, 2, 25, 210, 420, 640, 850 and 
1000 ng/mL. QC samples were prepared in-
dependently at four levels as HQC (high 
quality control) of 800 ng/mL, MQC (middle 
quality control) of 400 ng/mL, LQC (low 
quality control) of 2.9 ng/mL and LLOQC of 
1.01 ng/mL concentration. A working solu-
tion of internal standard (50 ng/mL) was 
prepared by diluting the stock solution in 
mixture of methanol and water (1:1). Until 
use all the solutions were stored at 2–8 °C. 
Sample preparation protocol 
For sample preparation all the solutions, 
i.e. CC standards, QC samples and unknown 
brain homogenate samples were prepared 
freshly. In detail, in a glass tube 600 µl ali-
quot of each sample + 50 µl (50 ng/mL) of 
IS was taken and added up with 5 % formic 
acid (200 µL) solution (for breaking of pro-
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tein binding) successively followed by vor-
tex for 5 minutes at 300 rpm. 5 ml of extrac-
tion mixture, i.e. ethyl acetate (650 mL) and 
acetonitrile (350 mL) prepared separately, 
was added and maintained at reciprocating 
shaker (20 minutes at 100 rpm). The tubes 
were made to spin in centrifuge (ten minutes 
at 4000 rpm and 4 ºC) and 4 mL of superna-
tant organic layer was transferred to another 
clean glass tube followed by drying in nitro-
gen stream at pressure NMT 20 psi and tem-
perature 50 ± 2.0 °C. Finally, dried elute was 
reconstituted in mobile phase (600 µl) and 
samples prepared were transferred to small 
vials for injection (10 µL) and analysis.  
Bioanalytical method validation 
FDA (2001) as reported (Ahmad et al., 
2014, 2015; Mustafa et al., 2013, Fai-
yazuddin et al., 2012; Wilson et al., 2005) 
were followed for the bioanalytical method 
validation of RT in brain homogenate 
whereas method linearity was determined by 
analysis of three standard plots which con-
tains eight non-zero concentrations. For the 
construction of calibration curve, ratio of 
peak area from analyte/IS were considered, 
via weighted (1/x2) linear least squares re-
gression of the brain concentrations and the 
measured peak area ratios. The lower limit of 
quantification (LLOQ) is the lowest concen-
tration of the calibration curve, which could 
be measured with acceptable accuracy and 
precision. The lower limit of quantification 
(LLOQ) was determined on the basis of sig-
nal-to-noise ratio (10:1) whereas RT extrac-
tion efficiency (recovery), evaluated via 
comparison between mean area response of 
six replicates of extracted samples (spiked 
before extraction) to that of extracted drug 
free brain homogenate samples (spiked after 
extraction), was performed at individual lev-
el of LQC, MQC and HQC levels. A like, the 
recovery of IS too was estimated. The repli-
cate analysis of RT brain samples was per-
formed on the same day in order to deter-
mine intra-day accuracy and precision. Six 
replicates of LLOQC, LQC, MQC, and HQC 
samples and calibration curve were included 
in the run. For the assessment of inter-day 
accuracy and precision, separated six preci-
sion and accuracy batches on three consecu-
tive days were analysed whereas slight 
changes in operating conditions (mobile 
phase composition, pH and flow rate) using 
LQC, MQC and HQC levels of QC samples 
were adopted for determination of robust-
ness, however, in order to evaluate rugged-
ness of the method, one batch of precision 
and accuracy, using different column (within 
the same manufacturer) run on the same in-
strument with the help of different analysts, 
was made to run. A total of six replicates for 
LLOQC, LQC, MQC, and HQC samples 
were run. 
Matrix effect 
Six samples, using six different brain 
homogenate batches, were prepared at LQC 
and HQC level in order to study the effect of 
matrix on quantification of analyte which 
was checked for %accuracy and precision 
(%CV) in both QC samples. In detail, back 
calculated values from QC’s nominal con-
centration were used to assess matrix effect. 
Following the specified storage condition for 
samples the analysis was performed and ma-
trix effect was investigated via post extrac-
tion spike method. The comparison for Peak 
area (A) of the analyte (known concentration 
of spiked blank brain homogenate (MQC)) 
with corresponding peak area (B) (obtained 
via direct injection of standard in the mobile 
phase) was performed whereas the ratio, i.e. 
A/B×100, is defined as the matrix effect. 
LOD and LOQ 
The standard deviation responses (SD) 
for the triplicate mobile phase blank injec-
tions along with slope of calibration (S) was 
used to calculate LLOD and LLOQ. Succes-
sively followed, LOD and LOQ were exper-
imentally determined as dilute known con-
centrations of RT until the average responses 
were approximately 3 or 10 times the stand-
ard deviation of the responses for triplicate. 
The following formula was used to deter-
mine the values for LOD and LOQ: 
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Slope
DeviationStdLOQ 10.   
Slope
DeviationStdLOD 3.3.   
Ex vivo stability 
Six replicates, at concentrations of 
(LQC) 2.9 ng/mL and (HQC) 800 ng/mL and 
exposed to different conditions of time and 
temperature, from brain homogenate were 
analysed to evaluate the stability of RT. Per-
centage stability was determined as: 
 
100x   
stock comparison of response Mean
stockstability  of response corrected Mean(%)Stability   
Long-term stability 
Six replicates of LQC and HQC, stored 
for one month at deep freezer (-80 °C), 
standard spiked brain homogenate sample 
were assessed for long term stability. 
Freeze-thaw stability 
Six replicates of LQC and HQC, under-
gone three consecutive freeze thaw cycles, 
i.e. from -20 °C to room temperature 
(+ 25 °C), brain homogenate were consid-
ered for evaluation in freeze-thaw stability 
studies.  
Bench-top stability 
After storage for 24 h in optimized con-
ditions, six set each of LQC and HQC were 
used to evaluate bench-top stability whereas 
QC samples were quantified against freshly 
spiked calibration curve standards. 
Post-processing stability 
Six set each of LQC and HQC of pro-
cessed samples, exposed to a temperature of 
10 °C in an autosampler for 24 h, were con-
sidered to determine the short term stability. 
Following specified storage conditions, sam-
ple were processed and analysed with con-
clusion, analyte exhibiting a precision (be-
low 15 %) and accuracy (85-115 %) are sta-
ble (Ahmad et al., 2014; Mustafa et al., 
2013).  
In vivo study 
Experimental animal 
The experimental animal study was per-
formed after proper approval (protocol ap-
proval No. 847), Animal Ethical Committee, 
Jamia Hamdard (New Delhi, India) which 
ensures to confirm according to National 
Guidelines on the Care and Use of Laborato-
ry Animals. One week before experiments; 
Wistar rats (n:6, weight: 300-400 g and age: 
8–10 weeks) were maintained in an envi-
ronment with controlled room temperature 
(25 ± 2 °C) and humidity (60 ± 5 %) for 12 h 
dark–light cycle. In addition standard pellet-
ed diet and water were used to feed animals. 
Before the experiment the rats were kept on 
fasting overnight.  
Experimental protocol 
This study used animal protocol already 
approved by Institutional Animal Ethics 
Committee, Jamia Hamdard. Prior to phar-
macokinetic studies, rats were fasted for 
12 h. The CS-Nanoparticles formulations 
(0.15 %:0.15 %::CS/TPP (v/v)) separately, 
encapsulating RT in a concentration of 
10 mg/kg after intranasal administration 
were quantified in Wistar rat striatum via 
bioanalytical method. Rats from different 
groups, i.e. control, API solution and nano-
particles treated, were sacrificed after 1 h in 
order to isolate striatum followed by homog-
enization with phosphate buffer (10 % w/v; 
pH 7.4), centrifugation (2500 × g) for 10 
minutes at 20 °C and subsequent collection 
of supernatant fractions. Until analysis col-
lected brain striatum samples were preserved 
at -80 °C for further investigation.  
 
RESULTS AND DISCUSSION 
The flavonoid RT is considered a low 
molecular weight compound, i.e. MW 
610.52 with an alcoholic group present in the 
structure which imparts it the sensitivity to 
be easily detected in positive ion mode. Var-
ious solvents, i.e. methanol and isopropyl 
alcohol were tried for mobile phase selection 
but they didn’t provide efficient chromato-
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graphic resolution. In addition, amongst the 
buffer system studied, ammonium formate 
(15 % v/v): formic acid (1 % v/v) buffer sys-
tem resulted in sharp peak and efficient sig-
nal response. Following different in-depth 
trials with change of solvents and buffer 
conditions etc., optimum chromatographic 
system for separation of RT achieved was as 
follows: mobile phase: Acetonitrile (85 % 
v/v): 2mM Ammonium Formate (15 % v/v): 
Formic Acid (0.1 % v/v); flow rate: 0.25 
mL/min and run time of 5.0 minutes (provid-
ed a baseline separation for RT and IS with-
out interference). The full-scan MS spectra 
for RT revealed, protonated molecule at m/z 
611.1023 as shown in Figure 1 whereas, dur-
ing direct infusion, IS mass spectra showed 
protonated molecule at m/z 271.1263 (Figure 
2). The optimum collision energies em-
ployed were 26.8 eV (RT) and 24.64 eV (IS) 
whereas capillary voltage of 4.5 kV was used 
in order to monitor precursor ions. 
The biological sample preparation tech-
niques most widely used are Protein precipi-
tation (PPT), liquid–liquid extraction (LLE) 
and solid-phase extraction (SPE). In detail, 
initially PPT method was applied for method 
development but due to strong ion suppres-
sion of the endogenous substance in brain 
homogenate PPT separation was not consid-
ered further for API separation. Although, 
aforementioned problem may be resolved 
with chromatographic separation but it will 
lead to run time sacrifice. Following differ-
ent procedures, LLE method was finally 
found to be the efficient for preparing RT 
striatum samples. In order to achieve obtain 
optimum recovery, seven organic extraction 
solvents were evaluated, i.e. ethyl acetate, 
chloroform, dichloromethane, acetonitrile, 
diethyl ether and tertiary butyl methyl ether 
(TBME), and n-hexane. To conclude, no 
solvent alone yielded the highest recovery 
alone except the extraction mixture, i.e. 
Ethyl Acetate (650 mL) and acetonitrile (350 
mL) which showed the highest recovery of 
> 86 %for RT and IS. Figure 3A represents 
chromatogram for brain homogenate, i.e. 
blank (extracted and reconstituted) while 
Figure 3B-D shows elution time for spiked 
RT brain homogenate sample and IS 
(50 ng/mL), i.e. at 2.67 min and 2.82 min 
respectively.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Typical 
chromatograms of (A) 
Extracted Blank Brain 
Homogenate, (B) LLOQ 
Extracted Brain Ho-
mogenate Rutin, (C) 
Extracted Brain Ho-
mogenate Rutin, (D) 
Extracted Brain Ho-
mogenate Tolbutamide 
IS (100 ng mL-1) ex-
tracted after spiking 
with Wistar rat-brain 
homogenate by selec-
tive reaction monitoring 
scan mode.  
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Preparation of optimized RT-CS-NPs 
More than 53 different concentration ra-
tio were evaluated for CS:TTP which 
showed a final concentration of ratio of 
(0.15 %:0.15 %) CS:TTP for the optimized 
nanoparticles (Data not shown in this paper). 
Different advance and delicate techniques 
such as TEM and SEM were utilized to eval-
uate the size and shape of CS-NPs. SEM re-
vealed a round and smooth surface morphol-
ogy as shown in Figure 4 whereas TEM 
showed sphericity and a particle size within 
range of 85–100 nm as shown in Figure 5, 
for RT-CS-NPs. The particle size, is alt-
hough within the range of optimum particle 
size for intranasal brain drug delivery as re-
ported (Ahmad et al., 2013, 2016), still other 
parameters were studied in order to optimize 
our formulation, i.e. TTP concentration, CS 
concentration, pH and stirring speed in order 
to obtain small particles, maximum loading 
with maximum encapsulation efficiency as 
well as PDI (0.206). Finally, optimized CS-
NPs with properties such as optimum parti-
cle size, loading capacity, and entrapment 
efficiency along with a sustained in vitro 
drug release profile of over 24 h were formu-
lated via ionotropic gelation method which 
was further subjected to Differential Scan-
ning Calorimetry (DSC) for entrapment of 
drug (Data not shown in this paper). 
 
Figure 4: Scanning electron microscopy images (SEM) of surface morphology of the prepared RT-
CS-NPs 
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Figure 5: Transmission electron microscopy (TEM) image of CS encapsulated with a rutin of opti-
mized NPs 
 
Bioanalytical method validation 
Linearity 
The RT calibration curve showed lineari-
ty at concentration range of 1-1000 ng/mL 
with least squares regression r2 ≥ 0.99 as 
well as accuracy (0.45-2.11 %) and precision 
(95.05-98.62 %.) ( %CV) for RT calibration 
curve standards.  
Accuracy and precision 
There was no interference of any endog-
enous peak from any of the batches with the 
retention time of analyte or IS. The selectivi-
ty of method is demonstrated via representa-
tive chromatogram from blank brain extract-
ed homogenate fortified with IS as well as 
blank brain homogenate fortified with RT as 
shown in Figure 3A. The mean recovery for 
RT, i.e. spiked brain homogenate (n=6) ob-
served at different level was as LQC 
(85.31 %), MQC (86.38 %) and HQC 
(87.01 %) whereas the IS recovery was 
79.28 %. For all the samples of RT at QC 
levels, the intra-batch and inter-batch preci-
sion (% CV) was in the ranges, i.e. 0.45-
1.82 % and 0.52-2.11 %, respectively where-
as intra-batch and inter-batch accuracy result 
were 98.01-98.62 % and 95.05-98.57 %, re-
spectively as shown in detail in Table 1. 
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Robustness 
The suitability of system was evaluating 
by observing the effects of different parame-
ters on the %age CV and recovery of RT at 
varying conditions as mobile phase ratio: 
Acetonitrile: Ammonium Formate (2 mM): 
Formic Acid at (84.9:14.9:0.09), (85:15:0.1) 
and (85.9:15.1:0.19) v/v/v concentration, 
mobile phase pH at 5.9, 6.1 and 6.3 and flow 
rate: 0.249, 0.250 and 0.260 mL/min. To 
conclude, robustness of the method was 
proved by obtaining low values for %CV of 
RT, i.e. 0.16 - 4.85 %) after small deliberate 
modifications in the already developed 
method of UHPLC as shown in Table 2A. 
Ruggedness 
For ruggedness one complete batch of 
RT was processed and analysed for precision 
and accuracy with the help of different ana-
lysts while utilizing different column and 
sets of solutions. The mean %accuracy and 
% correlation of variance for drugs (n = 6) 
showed a range of 95.04 - 98.49 and 0.62 - 
3.12, respectively as shown in Table 2B. 
Matrix effect 
The co-elution of some endogenous 
components present as normal part of biolog-
ical sample produces matrix effects observed 
as interference with peak retention from its 
actual expected position. The matrix effect 
for RT calculated as (A/B×100) revealed at 
different level was as LQC (% CV 3.85; n = 
6 each) and HQC (% CV 3.28; n = 6 each), 
1.36 % and 0.16, respectively. The % value 
for CV < 5 proves lack of matrix effects up-
on method. Using formic acid (5 %) as pro-
tein precipitating agent, RT showed no sig-
nificant ion suppression or enhancement in 
post-column infusion experiments as done 
with LLE.  
LOD and LOQ 
LOD and LOQ as estimated after exper-
imental analysis of spiked brain homogenate 
samples serially diluted with RT standard 
(until the ratio for signal-to-noise reaches 3 
and 10) resulted the value 0.09 ng/mL for 
LOD and 0.142 ng/mL for LOQ. 
 
 
 
Table 1: Precision and accuracy data for rutin 
Intra-batch 
 
Inter-batch 
 
QC ID Theoretical 
content 
(ng mL-1) 
Mean concentra-
tion observed  
(ng mL-1) 
Accuracya 
(%) 
CVb 
(%) 
Mean concentra-
tion observed  
(ng mL-1) 
Accuracya 
(%) 
CVb 
(%) 
LOQQC 1.01 0.99±0.011 98.01 1.11 0.96±0.018 95.05 1.88
LQC 2.90 2.86±0.059 98.62 1.82 2.85±0.060 98.28 2.11
MQC 400.00 392.60±4.009 98.15 1.02 389.99±4.222 97.50 1.08
HQC 800.00 788.12±3.547 98.52 0.45 788.52±4.099 98.57 0.52
Values (Mean ± SD) are derived from 6 replicates: aAccuracy (%) = Mean value of [(mean observed concentration)/(theoretical 
concentration)] × 100; bPrecision (%): Coefficient of variance (percentage) = standard deviation divided by mean concentration 
found×100; Theoretical contents; LOQQC: 1.01 ng mL-1, LQC: 2.90 ng mL-1; MQC: 400 ng mL-1; and HQC: 800 ng mL-1. 
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Table 2: Robustness of the method for rutin 
 
(A) Robustness 
Conditions LQC(2.90 ng mL-1) MQC(400 ng mL-1) HQC(800 ng mL-1)
Mobile Phase [ACN:10mM Ammonium Formate: Formic Acid (85:15:0.1 v/ v/v)] 
Negative level 
(84.9:14.9:0.09, n=3) 2.68±0.13 (4.85%) 379.99±1.98 (0.52%) 775.46±3.19 (0.41%) 
Zero level (85:15:0.1, n=3) 2.85±0.01 (0.35%) 392.84±2.23 (0.57%) 790.04±3.05 (0.38%) 
Positive level 
(85.9:15.1:0.19, n=3) 2.73±0.13 (4.76%) 381.94±2.38 (0.63%) 777.32±3.26 (0.42%) 
Flow Rate (0.25 ml /min)    
Negative level  
(0.249, n=3) 2.63±0.11 (4.18%) 378.45±2.75 (0.73%) 773.46±2.23 (0.28%) 
Zero level (0.25, n=3) 2.89±0.013 (0.44%) 393.46±1.22 (0.31%) 790.01±2.31 (0.29%) 
Positive level (0.26, n=3) 2.69±0.11 (4.08%) 381.27±2.01 (0.53%) 777.49±2.64 (0.34%) 
pH of Mobile Phase (Default pH=6.1) 
Negative level (5.9, n=3) 2.63±0.09 (3.42%) 377.99±2.04 (0.54%) 773.14±1.24 (0.16%) 
Zero level (6.1, n=3) 2.82±0.014 (0.49%) 392.01±2.13 (0.54%) 789.90±2.31 (0.29%) 
Positive level (6.3, n=3) 2.68±0.05 (1.86%) 381.03±2.55 (0.67%) 775.06±2.84 (0.36%) 
(B) Ruggedness 
QC ID Theoretical content 
(ng mL-1) 
Mean concentration observed  
(ng mL-1) 
Accuracy a 
(%) 
CV (%) b 
LOQQC 1.01 0.96±0.03 95.04 3.12 
LQC 2.90 2.80±0.076 96.55 2.71 
MQC 400.00 391.49±2.84 97.87 0.72 
HQC 800.00 787.91±4.95 98.49 0.62 
Values (Mean ± SD) are derived from 6 replicates: aAccuracy (%) = Mean value of [(mean observed concentra-
tion)/(theoretical concentration)] × 100; bPrecision (%): Coefficient of variance (percentage) = standard deviation divided by 
mean concentration found×100; Theoretical contents; LOQQC: 1.01 ng mL-1, LQC: 2.90 ng mL-1; MQC: 400 ng mL-1; and 
HQC: 800 ng mL-1 
 
Ex vivo stability 
Table 3 for ex vivo stability results shows 
the stability of RT over all the storage condi-
tions, i.e. freeze-thaw, long term, post-
processing and bench-top stability. Two lev-
els of quality control, i.e. LQC and HQC 
were considered for investigation of analyte 
stability in brain homogenate samples and 
the analyte recovery with respect to time ze-
ro was reviewed. In detail the stability results 
for %RT recovery were as recovery of 
98.94 % for LQC and 98.89 % for HQC after 
long term stability, i.e. 1 month: recovery for 
LQC and HQC in the range of 98.59 - 
97.87 % nd 99.74-99.14 respectively after 
freeze-thaw stability, i.e. after 1, 2 and 3 
freeze thaw cycles: a recovery of 99.29 % for 
LQC and 99.22 % for HQC observed with 
bench-top stability, i.e. 24 h and a recovery 
of 99.65 % for LQC and 98.88 % for HQC 
as observed after post-processing stability. 
In vivo study 
In order to estimate the concentration of 
RT in Wistar rats striatal tissue, the devel-
oped and validated UHPLC/ESI-Q-TOF-
MS/MS method as described in this article 
was applied which resulted as a successful 
application in order to find mean RT concen-
tration value (ng/mL) in striated waiter rats 
tissue already treated with RT-CS-NPS via 
i.n administration (as shown in Figure 6). To 
conclude the quantified results were as 
SHAM+CS-NPs, i.e. control group showed a 
value of 10.22 ± 0.0221 ng/mg of protein: 
the group treated with RT-CS-NPs showed 
maximum concentration level, i.e. 1449.33 ± 
44.88** ng/mg with P < 0.01 whereas max-
imum concentration for RT solution was 
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206.212 ± 14.99* ng/mg with P < 0.05. This 
high significant difference for RT concentra-
tion proves the advantage and effectiveness 
of i.n route of drug administration for drug 
delivery into brain. 
 
Figure 6: Pharmacokinetic plot of Rutin solution 
and Rutin loaded CS-NPs in brain after intrana-
sal administration at different time intervals. Sig-
nificance for Rutin solution and Rutin loaded CS-
NPs was determined as *p<0.05 and **p<0.01 
when compared with SHAM+CS-NPs group 
(Placebo control group) 
CONCLUSION 
The rapid, selective and sensitive proper-
ties and above all the detection limit upto 
picogram level supports the potential of the 
develop method for quantification of RT via 
UHPLC/ESI-Q-TOF-MS/MS in rat brain 
homogenate The recovery for three analytes 
in brain homogenate after extraction proce-
dures, i.e. >86 % as well as the results ob-
tained for accuracy and precision, linearity 
and stability, i.e. bench-top, long term, 
freeze thaw stability and post processing sta-
bility as well as matrix effect were found 
within acceptable range of limits. In addi-
tion, the developed quantification method 
was applied successfully for in vivo studies 
in brain homogenate from Wistar rat’s brain 
with acceptable accuracy and precision range 
and adequate sensitivity hence supporting 
the fact, the developed quantification method 
is efficiently applicable in further clinical 
studies. 
 
 
 
 
 
 
Table 3: Ex vivo stability data for rutin 
Conditions LQC (2.90 ng mL-1) HQC (800.00 ng mL-1) 
Long term stability; recovery (ng) after storage (-80 °C) 
Previous day 2.84±0.04 795.00±2.170 
30th Day 2.81±0.05 (98.94%) 786.22±2.410 (98.89%) 
Freeze–thaw stress; recovery (ng) after freeze–thaw cycles (-20 °C to 25°C) 
Pre-Cycle 2.83±0.04 796.22±1.621 
First Cycle 2.79±0.04 (98.59%) 794.14±2.141 (99.74%) 
Second Cycle 2.77±0.03 (97.88%) 792.27±2.137 (99.50%) 
Third Cycle 2.75±0.03 (97.87%) 789.43±2.715 (99.14) 
Heating-cooling stress; recovery (ng) after Heating-cooling cycles (50 °C to 4°C) 
Pre-Cycle 2.83±0.02 796.89±1.76 
First Cycle 2.79±0.03 (98.58%) 792.41±2.59 (99.43%) 
Second Cycle 2.75±0.04 (97.17%) 787.29±3.84 (98.79%) 
Third Cycle 2.70±0.04 (95.40%) 780.99±2.99 (98.00%) 
Bench-top stability; recovery (ng) at room temperature (25 °C) 
0 hr 2.81±0.04 791.27±1.660 
24 hr 2.79±0.03 (99.29%) 785.07±1.521 (99.22%) 
Post-processing stability; recovery (ng) after storage in auto sampler (4 °C) 
0 hr 2.84±0.02 792.00±1.991 
24 hr 2.80±0.03 (99.65%) 783.15±2.121 (98.88%) 
Values (Mean ±SD) are derived from six replicates. Figures in parenthesis represent analyte concentration (%) relative to time 
zero. Theoretical contents; LOQQC: 1.01 ng mL-1, LQC: 2.9 ng mL-1; MQC: 400 ng mL-1; and HQC: 800 ng mL-1 
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